Tolvaptan + placebo
Phase 3Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Heart Failure
Conditions
Acute Heart Failure
Trial Timeline
— → —
NCT ID
NCT01733134About Tolvaptan + placebo
Tolvaptan + placebo is a phase 3 stage product being developed by Thermo Fisher Scientific for Acute Heart Failure. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01733134. Target conditions include Acute Heart Failure.
What happened to similar drugs?
20 of 20 similar drugs in Acute Heart Failure were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01733134 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Acute Heart Failure